• The Korean Journal of Pain
• /
• v.32 no.3
• /
• pp.196-205
• /
• 2019

Background: Hypertonic saline (HS) injections for decompressive neuroplasty (DN) can cause pain. We assessed whether a continuous infusion of HS through an infusion pump would reduce injection-related pain compared with repeated bolus administrations. Methods: Fifty patients scheduled for DN were randomized to either the bolus injection or the continuous infusion group. After appropriately placing the epidural catheter, 4 mL of 5% NaCl was injected as four boluses of 1 mL each at 15-minute intervals or infused over 1 hour using an infusion pump. The severity of pain induced by HS injection, as measured by the 11-point numerical rating scale (NRS), was the primary outcome. The severity of low back or lower extremity pain, as measured by the 11-point NRS and Oswestry Disability Index (ODI), 3 months following the procedure, was the secondary outcome. Results: Data from 21 patients in the bolus group and 23 in the continuous infusion group were analyzed. No statistically significant difference in injection-related pain was identified between the two groups during the initial HS administration (P = 0.846). However, there was a statistically significant reduction in injection-related pain in the continuous infusion group compared to the bolus injection group from the second assessment onwards (P = 0.001, < 0.001, and < 0.001, respectively). No significant between-group differences in the NRS and ODI scores 3 months post-procedure were noted (P = 0.614 and 0.949, respectively). Conclusions: Our study suggests that administering HS through a continuous infusion is a useful modality for reducing HS injection-related pain during DN.

• Journal of the Korean Society of Manufacturing Technology Engineers
• /
• v.22 no.2
• /
• pp.235-240
• /
• 2013

This paper presents a disposable microfluidic infusion pump using the restoring force of elastomeric membrane of Polydimethylsiloxane. Microfluidic infusion pump consists of hydraulic resistance control part, elastomeric blister actuator part, drug inlet and outlet. Expanded elastomeric blister actuator continuously pushes liquid in the chamber to outlet. At same time, microchannel diameter near the outlet was controlled by thin elastomeric membrane in hydraulic resistance control part. Eventually flow rate of infused liquid is controlled by air pressure. In experimental study, the amount of the filled liquid in the blister is precisely controlled by the height of the blister. Flow rate of infused liquid could be controlled, that is, controlled release of the drug over time was possible by adjusting hydraulic resistance and restoring pressure with the blister actuator.

• The KSFM Journal of Fluid Machinery
• /
• v.12 no.3
• /
• pp.31-37
• /
• 2009

This paper presents a implantable intrathecal drug infusion pump for pain control in cancer patients. This device consists of micropump module, drug reservoir module and control module. The micropump module using cam-follower mechanism composed of small-sized four cams and four followers. Each followers is driven by a cam and liquid is discharged by a sequential reciprocal motion of the followers. The advantage of this structure is that it allows the pump to be clean and valveless. The drug reservoir module composed of drug chamber, gas chamber and diaphragm. The control module composed of battery, wireless communication unit and controller. To design a small-sized, low power pump some analysis were performed to determine the design parameters. To verify the feasibility of the experiment, a prototype was manufactured and its operating characteristics were investigated. Experimental results were in accordance with the expected results obtained from analysis.

• Proceedings of the KOSOMBE Conference
• /
• v.1998 no.11
• /
• pp.49-49
• /
• 1998

• The Korean Nurse
• /
• v.20 no.3 s.111
• /
• pp.81-82
• /
• 1981

• The Korean Journal of Pain
• /
• v.12 no.2
• /
• pp.200-204
• /
• 1999

Background: Patient-controlled analgesia (PCA) has proven to be safe and effective in children from age 5 years, and older and compares favourably with continuous morphine infusion in the older child. We compared fentanyl and butorphanol for opioid use in PCA with ketorolac to determine a suitable drug combination for post-tonsillectomy pain control. Methods: We studied 60 patients, aged 5~12 yrs, undergoing tonsillectomy with or without adenoidectomy under general anesthesia using $N_2O-O_2$-enflurane. Patients were randomly assigned to receive fentanyl $250\;{\mu}g$ (Group 1: n=30) or butorphanol 5 mg (Group 2: n=30) mixed with ketorolac 90 mg and ondansetron 4 mg diluting 100 ml of 5% D/W solutions intravenously via PCA pump after operation. PCA pump were programmed to deliver a 0.05 ml/kg loading dose, 0.01 ml/kg/hr basal infusion, 0.01 ml/kg on demand bolus, 6 min lockout intervals between doses and 4 bolus hourly limit. Total infusion dosage of PCA drug, VAS pain scores, side effects and satisfaction score of both groups were monitored for 48 hrs. Results: Total infusion dosages were fentanyl $170.6\;{\mu}g$ with ketorolac 61.4 mg (Group 1) and butorphanol 2.8 mg with ketorolac 50.4 mg (Group 2). Total infusion dosage, quality of analgesia, side effects and overall satisfaction didn't differ between two groups. Conclusions: Both fentanyl and butorphanol mixed with ketorolac were effective for post-tonsillectomy pain control using PCA pump in children as young as 5 years old.

• Journal of The Korean Dental Society of Anesthesiology
• /
• v.2 no.2 s.3
• /
• pp.97-100
• /
• 2002

Background: Patient-controlled sedation (PCS) has been blown for a safe and effective sedative method on the same pharmacological concepts of patient-controlled analgesia. Many different kinds of infusion devices have been used but they often have too long nominal infusion rate and lockout time. $Perfuser^{\circledR}$ fm (B. Braun, Germany) is a new PCA device with 999.9 ml/hr nominal infusion rate and minimum 1 min lockout time. In this study, the feasibility of propofol PCS using $Perfuser^{\circledR}$ fm was examined in order to provide a safe satisfactory sedation for dental patients. Methods: Eleven healthy patients presenting for oral surgery were studied. Propofol PCS was performed using $Perfuser^{\circledR}$ fm, which was set to deliver a bolus dose of 5 mg with 999.9 ml/hr nominal infusion rate and 1 min lockout time. Propofol loading dose was randomly assigned to a bolus dose ${\times}$ 0, 2, and 3 (initial bolus). Patients were told to press the bolus button as often as they needed to relieve discomfort. Results: Total infused dose of propofol was mean 1.8 mg/kg/hr and D (Delivery)/A (Attempt) ratio was mean 72.8%. All patients was awake and there were no clinically significant intraoperative side effects during the sedation. Almost all patients were very satisfied with this type of PCS. Conclusion: Propofol PCS using $Perfuser^{\circledR}$ fm infusion pump provided good conscious sedation for dental procedures.

• Journal of Chest Surgery
• /
• v.15 no.1
• /
• pp.35-39
• /
• 1982

Cold blood potassium cardioplegia, by two types of the infusion systems, was used in 45 patients who were undergone the open cardiac operation. Method A [in 25 patients] was the syringe infusion system and method B [in 20 patients] was the pump infusion system. Cold blood potassium cardioplegic solution was used less amount on method B than method A. Serum potassium was often increased significantly on method A as a result of excessive infusion of cold blood potassium cardioplegic solution. But method B, excessive infusion of cold blood potassium cardioplegic solution was prevented by reperfusion of the previous infused cold blood potassium cardioplegic solution through the recirculation system. Alteration of infused rate and concentration of potassium in cold blood potassium cardioplegic solution during infusion [which might be suggested on the method A] could be controlled on method B.

• Proceedings of the KOSOMBE Conference
• /
• v.1998 no.11
• /
• pp.127-128
• /
• 1998

It is necessary to maintain constant intravenous (IV) infusion rate. While infusion pump is able to control infusion rate with great accuracy, its rather large size and weight make it difficult for patients to move around. The most commonly used infusion device is gravity IV infusion set with its administration chamber being clamped according to the observed drip rate. In this case it may be easier and more accurate to maintain IV rate to given value if we automate the drip-counting process and tube-clamping work by electronic devices. We calculated volume infusion rate of specific fluid using optical drip rate meter which we had developed. To regulate fluid flow rate, we equipped the rate meter which we had developed with a miniaturized clamping apparatus using DC motor. Also, we Implemented drip detection and clamp control algorithm with PIC16C73 $\mu$-controller (Microchip). This system provides user interface through LCD display and key buttons.

• Journal of Biomedical Engineering Research
• /
• v.24 no.1
• /
• pp.45-53
• /
• 2003

Based on the 4-compartmental pharmacokinetic model developed in PART1, target-controlled infusion(TCI) pump system was designed and evaluated. The TCI system consists of digital board including microcontroller and digital signal process(DSP), analog board, motor-driven actuator, user friendly interface, power management and controller. It provides two modes according to the drugs: plasma target concentration and effect target concentration. Anaesthetist controls the depth of anaesthesia for patients by adjusting the required concentration to maintain both plasma and effect site in drug concentration. The data estimated in DSP include infusion rate, initial load dose, and rotation number of motor encoder. During TCI operation, plasma concentration. effect site concentration, awaken concentration, context-sensitive decrement time and system error information are displayed in real time. Li-ion battery guarantees above 2 hours without power line failure. For high reliability of the system, two microprocessors were used to perform independent functions for both pharmacokinetic algorithm and motor control strategy.